Correction
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
N Engl J Med 2012; 366:284January 19, 2012
- Article
A Phase 3 Trial of Bevacizumab in Ovarian Cancer (Original Article, N Engl J Med 2011 ; 365 : 2484 - 2496) . In the Patients subsection of Results (page 2487), the final sentence should have read, “. . . and 26% had more than 1.0 cm of residual disease after surgical debulking,” rather than “. . . and 26% had 71.0 cm of residual disease.” We regret the error. The article is correct at NEJM.org.
